Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
While biopharma must strategically choose between GLP-1 follow-ons, innovative MoAs, or combination therapies, payers must justify broader coverage by factoring in the long-term economic benefits of prevention
Adding it to a metabolic peptide sounds contradictory, and that apparent contradiction is exactly why the triple agonists are scientifically interesting
We provide access to third party testing documentation so you can review the quality and verification of each batch
The most common side effect during this phase is subtle appetite reduction
Acosta Group found that 85% of those experiencing side effects buy items to offset them, split evenly between in-store and online purchases